Best Biotech Stocks to Buy Now (2024)Top biotech stocks in 2024 ranked by overall Zen Score. See the best biotech stocks to buy now, according to analyst forecasts for the biotechnology industry.
Industry: Biotechnology
| Ticker | Company | Country | Market Cap | Shares | Institutional % | Insider % | Net Insider (L12M) | Net Insider (L3M) |
|---|---|---|---|---|---|---|---|---|
| TERN | TERNS PHARMACEUTICALS INC | United States | $299.98M | 64,651,693 | 72.52% | 27.48% | Net Selling | Net Selling |
| ACAD | ACADIA PHARMACEUTICALS INC | United States | $2.69B | 164,771,521 | 71.22% | 28.78% | Net Buying | Net Selling |
| PMCB | PHARMACYTE BIOTECH INC | United States | $17.95M | 8,464,824 | 12.86% | 13.29% | ||
| TBPH | THERAVANCE BIOPHARMA INC | Cayman Islands | $440.23M | 48,164,708 | 60.28% | 39.72% | Net Selling | Net Selling |
| SNSE | SENSEI BIOTHERAPEUTICS INC | United States | $25.07M | 25,070,980 | 11.82% | 71.99% | Net Selling | Net Selling |
| RLAY | RELAY THERAPEUTICS INC | United States | $807.41M | 131,179,034 | 72.36% | 27.64% | Net Selling | Net Selling |
| DMAC | DIAMEDICA THERAPEUTICS INC | United States | $96.03M | 37,958,000 | 10.12% | 55.46% | Net Buying | |
| MNKD | MANNKIND CORP | United States | $1.13B | 270,418,215 | 30.01% | 69.99% | Net Buying | Net Buying |
| OCUL | OCULAR THERAPEUTIX INC | United States | $624.24M | 148,627,439 | 49.43% | 21.84% | Net Buying | Net Buying |
| ADPT | ADAPTIVE BIOTECHNOLOGIES CORP | United States | $378.69M | 145,092,271 | 62.07% | 37.93% | Net Selling | Net Selling |
| PHAR | PHARMING GROUP NV | Netherlands | $701.27M | 671,073,243 | 0.00% | 0.00% | ||
| URGN | UROGEN PHARMA LTD | Israel | $471.57M | 34,122,087 | 62.74% | 29.32% | Net Buying | Net Selling |
| OCGN | OCUGEN INC | United States | $303.64M | 257,325,264 | 10.16% | 11.93% | Net Selling | |
| PULM | PULMATRIX INC | United States | $7.60M | 3,652,285 | 4.28% | 95.72% | ||
| FOLD | AMICUS THERAPEUTICS INC | United States | $3.00B | 295,382,614 | 66.56% | 33.44% | Net Selling | Net Selling |
| RXRX | RECURSION PHARMACEUTICALS INC | United States | $1.84B | 234,653,272 | 75.27% | 24.73% | Net Selling | Net Selling |
| CLLS | CELLECTIS SA | France | $138.40M | 55,583,768 | 17.66% | 0.00% | ||
| IMRN | IMMURON LTD | Australia | $13.84M | 227,798,346 | 0.00% | 0.00% | ||
| HOOK | HOOKIPA PHARMA INC | United States | $79.75M | 98,950,107 | 35.22% | 26.83% | Net Buying | |
| CANF | CAN-FITE BIOPHARMA LTD | Israel | $7.83M | 1,359,837,393 | 0.02% | 0.00% | ||
| SILO | SILO PHARMA INC | United States | $5.35M | 2,843,634 | 5.65% | 6.35% | Net Buying | Net Buying |
| BLRX | BIOLINERX LTD | Israel | $41.86M | 1,086,589,165 | 0.10% | 0.00% | ||
| IPHA | INNATE PHARMA SA | France | $193.09M | 80,453,282 | 0.16% | 0.00% | ||
| AADI | AADI BIOSCIENCE INC | United States | $41.25M | 24,554,205 | 26.99% | 73.01% | Net Selling | Net Selling |
| CRVO | CERVOMED INC | United States | $154.20M | 6,170,479 | 0.47% | 99.53% | ||
| PSTX | POSEIDA THERAPEUTICS INC | United States | $197.80M | 96,489,127 | 46.85% | 40.59% | Net Selling | Net Selling |
| RGNX | REGENXBIO INC | United States | $713.51M | 44,427,555 | 76.15% | 23.85% | Net Selling | Net Buying |
| TCRT | ALAUNOS THERAPEUTICS INC | United States | $18.57M | 16,012,479 | 53.36% | 46.64% | Net Selling | |
| MRNA | MODERNA INC | United States | $40.57B | 382,073,208 | 67.30% | 21.66% | Net Selling | Net Selling |
| RPTX | REPARE THERAPEUTICS INC | Canada | $132.87M | 42,182,177 | 61.13% | 38.87% | Net Buying | Net Selling |
| MRVI | MARAVAI LIFESCIENCES HOLDINGS INC | United States | $1.91B | 251,399,871 | 35.06% | 64.94% | Net Selling | Net Selling |
| STOK | STOKE THERAPEUTICS INC | United States | $541.29M | 46,303,743 | 40.29% | 59.71% | Net Selling | Net Selling |
| BRTX | BIORESTORATIVE THERAPIES INC | United States | $8.33M | 6,769,919 | 0.28% | 99.72% | Net Buying | Net Buying |
| LEXX | LEXARIA BIOSCIENCE CORP | Canada | $28.22M | 12,885,673 | 8.82% | 4.82% | ||
| PCSA | PROCESSA PHARMACEUTICALS INC | United States | $6.94M | 2,855,981 | 23.32% | 76.68% | Net Buying | Net Buying |
| KRON | KRONOS BIO INC | United States | $58.89M | 60,095,013 | 44.51% | 42.51% | Net Buying | Net Selling |
| PASG | PASSAGE BIO INC | United States | $67.83M | 55,598,796 | 43.60% | 56.40% | Net Buying | Net Selling |
| KURA | KURA ONCOLOGY INC | United States | $1.45B | 76,136,963 | 90.77% | 9.23% | Net Buying | Net Selling |
| KTTA | PASITHEA THERAPEUTICS CORP | United States | $7.55M | 1,042,415 | 2.22% | 97.78% | Net Buying | |
| OMGA | OMEGA THERAPEUTICS INC | United States | $129.61M | 55,154,985 | 57.75% | 42.25% | Net Selling | |
| ORIC | ORIC PHARMACEUTICALS INC | United States | $516.77M | 67,375,847 | 70.31% | 29.69% | Net Selling | Net Selling |
| NXTC | NEXTCURE INC | United States | $35.99M | 27,903,027 | 47.82% | 50.20% | ||
| SNDX | SYNDAX PHARMACEUTICALS INC | United States | $1.75B | 84,965,486 | 91.35% | 8.65% | Net Buying | Net Buying |
| IPSC | CENTURY THERAPEUTICS INC | United States | $204.18M | 64,817,863 | 27.27% | 59.23% | Net Selling | Net Selling |
| IMRX | IMMUNEERING CORP | United States | $41.88M | 29,283,272 | 53.75% | 46.25% | Net Selling | Net Selling |
| ACET | ADICET BIO INC | United States | $148.70M | 82,153,984 | 40.62% | 19.50% | Net Buying | |
| PMVP | PMV PHARMACEUTICALS INC | United States | $87.97M | 51,443,488 | 62.78% | 37.22% | Net Buying | |
| VRCA | VERRICA PHARMACEUTICALS INC | United States | $282.08M | 42,418,553 | 41.10% | 58.90% | Net Buying | |
| DYAI | DYADIC INTERNATIONAL INC | United States | $43.17M | 28,974,105 | 7.98% | 92.02% | ||
| MORF | MORPHIC HOLDING INC | United States | $1.40B | 50,093,588 | 64.32% | 35.68% | Net Buying | Net Buying |
| EQ | EQUILLIUM INC | United States | $63.81M | 35,254,752 | 21.71% | 40.89% | Net Buying | |
| LVTX | LAVA THERAPEUTICS NV | Netherlands | $69.40M | 26,289,087 | 22.20% | 0.00% | ||
| AVIR | ATEA PHARMACEUTICALS INC | United States | $310.57M | 84,164,545 | 65.45% | 25.19% | Net Selling | Net Selling |
| CGEM | CULLINAN THERAPEUTICS INC | United States | $829.01M | 43,065,645 | 48.26% | 51.74% | Net Selling | Net Buying |
| ACST | ACASTI PHARMA INC | Canada | $27.53M | 9,399,404 | 6.08% | 64.72% | Net Buying | |
| GLTO | GALECTO INC | United States | $18.14M | 27,112,697 | 14.20% | 24.86% | Net Selling | |
| CLSD | CLEARSIDE BIOMEDICAL INC | United States | $94.15M | 74,721,139 | 10.37% | 36.40% | Net Buying | Net Buying |
| LGND | LIGAND PHARMACEUTICALS INC | United States | $1.25B | 17,705,287 | 14.99% | 85.01% | Net Selling | Net Buying |
| CBUS | CIBUS INC | United States | $375.01M | 24,132,009 | 14.04% | 85.96% | Net Buying | |
| SABS | SAB BIOTHERAPEUTICS INC | United States | $36.99M | 9,225,494 | 40.51% | 59.49% | Net Buying | |
| CGON | CG ONCOLOGY INC | United States | $2.41B | 66,636,252 | 0.00% | 16.44% | Net Buying | Net Buying |
| CRMD | CORMEDIX INC | United States | $285.35M | 54,981,102 | 34.05% | 10.98% | Net Buying | Net Buying |
| XENE | XENON PHARMACEUTICALS INC | Canada | $3.02B | 75,432,482 | 95.45% | 3.29% | Net Selling | Net Selling |
| VRAX | VIRAX BIOLABS GROUP LTD | United Kingdom | $1.27M | 1,811,540 | 7.37% | 0.00% | ||
| ATHA | ATHIRA PHARMA INC | United States | $73.59M | 38,326,652 | 57.11% | 31.41% | Net Buying | |
| ARTL | ARTELO BIOSCIENCES INC | United States | $4.33M | 3,227,700 | 0.76% | 25.83% | ||
| BNTC | BENITEC BIOPHARMA INC | Australia | $17.99M | 2,592,434 | 46.20% | 28.78% | ||
| BDTX | BLACK DIAMOND THERAPEUTICS INC | United States | $264.28M | 51,717,849 | 60.10% | 39.90% | Net Buying | Net Buying |
| EXAI | EXSCIENTIA PLC | United Kingdom | $501.55M | 125,702,396 | 24.77% | 0.00% | ||
| DOMH | DOMINARI HOLDINGS INC | United States | $16.02M | 5,934,917 | 7.25% | 92.75% | Net Buying | Net Buying |
| PRLD | PRELUDE THERAPEUTICS INC | United States | $221.88M | 54,920,594 | 52.43% | 47.57% | Net Buying | Net Selling |
| NRIX | NURIX THERAPEUTICS INC | United States | $607.50M | 49,150,794 | 84.44% | 15.56% | Net Selling | Net Selling |
| VCEL | VERICEL CORP | United States | $2.19B | 48,290,164 | 91.22% | 8.78% | Net Selling | Net Selling |
| PCVX | VAXCYTE INC | United States | $6.51B | 108,407,730 | 83.78% | 16.22% | Net Buying | Net Buying |
| NKTX | NKARTA INC | United States | $337.02M | 49,416,186 | 53.86% | 46.14% | Net Buying | Net Buying |
| XBIT | XBIOTECH INC | United States | $250.00M | 30,450,881 | 11.32% | 45.18% | ||
| ZNTL | ZENTALIS PHARMACEUTICALS INC | United States | $779.50M | 70,960,165 | 73.56% | 26.44% | Net Buying | Net Selling |
| STRO | SUTRO BIOPHARMA INC | United States | $213.55M | 62,441,963 | 78.85% | 21.15% | Net Selling | Net Selling |
| CNTA | CENTESSA PHARMACEUTICALS PLC | United Kingdom | $895.73M | 100,305,850 | 71.06% | 14.21% | Net Selling | Net Selling |
| ANNX | ANNEXON INC | United States | $413.22M | 90,025,573 | 76.31% | 23.69% | Net Buying | Net Selling |
| LTRN | LANTERN PHARMA INC | United States | $58.65M | 10,741,324 | 10.76% | 66.23% | Net Selling | Net Selling |
| ADMA | ADMA BIOLOGICS INC | United States | $1.47B | 228,220,236 | 74.12% | 24.57% | Net Selling | Net Selling |
| VXRT | VAXART INC | United States | $114.40M | 173,861,684 | 9.16% | 69.71% | Net Selling | Net Selling |
| LPTX | LEAP THERAPEUTICS INC | United States | $81.15M | 25,600,137 | 12.25% | 87.75% | ||
| ABEO | ABEONA THERAPEUTICS INC | United States | $87.26M | 27,355,037 | 25.76% | 74.24% | Net Buying | Net Buying |
| QNCX | QUINCE THERAPEUTICS INC | United States | $44.51M | 43,215,233 | 15.43% | 84.57% | Net Buying | |
| GDTC | CYTOMED THERAPEUTICS LTD | Singapore | $25.39M | 11,540,000 | 0.04% | 57.45% | ||
| NUVB | NUVATION BIO INC | United States | $573.90M | 219,046,219 | 50.10% | 49.90% | Net Buying | |
| GPCR | STRUCTURE THERAPEUTICS INC | United States | $1.81B | 139,794,124 | 30.46% | 15.04% | ||
| ALDX | ALDEYRA THERAPEUTICS INC | United States | $232.05M | 58,895,768 | 59.63% | 34.19% | Net Selling | Net Buying |
| CDTX | CIDARA THERAPEUTICS INC | United States | $59.30M | 4,561,751 | 61.60% | 38.40% | Net Selling | Net Selling |
| PTIX | PROTAGENIC THERAPEUTICS INC | United States | $6.96M | 4,435,132 | 2.55% | 1.03% | Net Buying | |
| TYRA | TYRA BIOSCIENCES INC | United States | $793.59M | 52,521,050 | 59.50% | 40.50% | Net Buying | Net Buying |
| EPIX | ESSA PHARMA INC | Canada | $270.74M | 44,238,147 | 73.10% | 26.90% | Net Buying | Net Buying |
| ENTX | ENTERA BIO LTD | Israel | $70.96M | 35,481,341 | 11.45% | 3.79% | Net Buying | |
| ERAS | ERASCA INC | United States | $284.81M | 151,494,161 | 44.64% | 55.36% | Net Buying | |
| VRNA | VERONA PHARMA PLC | United Kingdom | $1.24B | 646,524,958 | 10.44% | 55.94% | Net Selling | Net Selling |
| MACK | MERRIMACK PHARMACEUTICALS INC | United States | $213.82M | 14,516,170 | 23.49% | 76.51% | Net Buying | |
| CELC | CELCUITY INC | United States | $480.25M | 30,453,120 | 52.40% | 15.32% | Net Selling | Net Selling |
| CNTB | CONNECT BIOPHARMA HOLDINGS LTD | China | $74.94M | 55,102,954 | 12.92% | 0.00% |
Biotech Stocks FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.